CAS Space and Guangzhou Laboratory to test space-based drug payloads on Lihong-2 in 2027
CAS Space (Zhongke Yuhang) deepened its partnership with Guangzhou Laboratory to jointly develop space-based pharmaceutical payloads. The first batch is scheduled for suborbital flight verification in Q1 2027 aboard the Lihong-2 reusable launch vehicle, conducting protein and small-molecule drug crystallization experiments as early technical validation for space pharmaceutical equipment.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
China's CAS Space Deepens Space Pharma Partnership, Plans 2027 Suborbital Experiment
On September 28, CAS Space (Zhongke Yuhang) announced a deepened partnership with Guangzhou Laboratory to jointly develop and verify space-based pharmaceutical payloads. The first batch of payloads is scheduled for the first quarter of 2027, aboard the Lihong-2 reusable launch vehicle for suborbital flight testing. The experiments will focus on protein and small-molecule drug crystallization, serving as early technical verification for space pharmaceutical equipment. Under the agreement, Guangzhou Laboratory will define the scientific questions, provide experimental protocols, samples, ground controls, and result analysis. Its core team, led by researcher Xu Qiang, specializes in high-end medical devices, MEMS sensing, and microscopic imaging, and will convert mature biomedical automation and in-situ observation capabilities into payload functions. CAS Space will provide the space platform, environmental control, system interfaces, launch and return services, and mission organization. The two parties will jointly design the payload engineering. In equipment development, they aim to enhance automation in experimental operations and process observation, including developing a full-field cell imager for space biology with miniaturized, lightweight, and low-power designs featuring auto-focus, continuous imaging, and image analysis for autonomous operation.
Read sourceChina's CAS Space Deepens Space Pharma Collaboration, Plans 2027 Suborbital Test
According to a report from Jin10 on September 28, CAS Space (Zhongke Yuhang) and the Guangzhou Laboratory are jointly developing and researching space-based pharmaceutical payloads, and plan to jointly conduct space pharmaceutical scenario verification. The first batch of payloads is scheduled to conduct suborbital flight verification in the first quarter of 2027, using the Lihong-2 reusable launch vehicle. The mission will implement protein and small-molecule drug crystallization experiments and carry out preliminary technical verification of space pharmaceutical equipment. The report was sourced from Securities Times.
Zhongke Yuhang Deepens Space Pharma Cooperation, Lihong-2 to Carry Payload in 2027
Zhongke Yuhang (CAS Space) has deepened its collaboration with the Guangzhou Laboratory to jointly develop and test space-based pharmaceutical payloads. The first batch of payloads is scheduled for a suborbital flight verification in the first quarter of 2027, aboard the Lihong-2 reusable launch vehicle. The mission will conduct crystallization experiments on proteins and small-molecule drugs, serving as an early technical validation for space-based pharmaceutical equipment. The information was sourced from People's Financial News.
Read sourceShow 2 older updatesHide older updates
CAS Space Deepens Space Pharma Cooperation, Lihong-2 to Carry Medical Payload on Maiden Flight in 2027
According to a report from People's Financial Information on September 28, CAS Space (Zhongke Yuhang) has deepened its cooperation with the Guangzhou Laboratory to jointly develop and test space-based pharmaceutical payloads. The first batch of payloads is scheduled to conduct a suborbital flight verification mission in the first quarter of 2027 aboard the Lihong-2 reusable launch vehicle. The mission will involve protein and small-molecule drug crystallization experiments, serving as an early technical validation for space-based pharmaceutical equipment.
Read sourceCAS Space Deepens Space Pharma Cooperation, Lihong-2 to Carry Payload in 2027
According to a report from Securities Times on September 28, China-based aerospace company CAS Space (Zhongke Yuhang) has deepened its cooperation with the Guangzhou Laboratory on the joint development of space-based pharmaceutical payloads. The two parties plan to conduct joint verification of space pharmaceutical scenarios. The first batch of payloads is scheduled to fly aboard the Lihong-2 reusable launch vehicle in the first quarter of 2027 for suborbital flight verification. The mission will carry out protein and small-molecule drug crystallization experiments and conduct preliminary technology verification for space pharmaceutical equipment.
Read source